Literature DB >> 10614917

Neuroradiological diagnosis in thyroid-associated orbitopathy.

W Müller-Forell1, S Pitz, W Mann, G J Kahaly.   

Abstract

No renunciation can be made of modern imaging techniques in primary diagnosis as well as in the course of endocrine orbitopathy. Even in times of cost reduction of the public health and although expansive CT and MR play a constant role in the interdisciplinary challenge, concerning the treatment of these patients. Both methods show the actual objective morphological findings, MR giving additional information concerning the acuteness (T2 relaxation time) or chronicity (fatty degeneration), which is of great importance for the chosen therapy. CT and MR is mandatory for the control of the clinical course after conservative, surgical and/or radiotherapeutic therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10614917     DOI: 10.1055/s-0029-1212180

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  5 in total

Review 1.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

Review 2.  [Inflammatory diseases of the orbit].

Authors:  A Zimmer; W Reith
Journal:  Radiologe       Date:  2008-12       Impact factor: 0.635

3.  Update on advanced imaging options for thyroid-associated orbitopathy.

Authors:  Michael P Rabinowitz; Jacqueline R Carrasco
Journal:  Saudi J Ophthalmol       Date:  2012-10

Review 4.  Recent developments in Graves' ophthalmopathy imaging.

Authors:  G J Kahaly
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

5.  Influence of Clinically Active Graves' Ophthalmopathy on Spherical Equivalent and Visual Acuity.

Authors:  Jasenka Petrovic Jurcevic; Marko Jurcevic; Mateja Jagic; Anamarija Jazbec; Kresimir Mandic; Jelena Juri Mandic
Journal:  Clin Ophthalmol       Date:  2022-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.